You just read:

ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors

News provided by

ARMO BioSciences, Inc.

Jun 03, 2017, 09:10 ET